Media coverage
103Media coverage
Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-... Media name/outlet CNN Money Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Reuters Country United Kingdom Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet PR Newswire Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Individual.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Individual.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Nasdaq Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Wall Street Select Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Town Hall Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet RCL Advisors Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Reliance Trust Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Fat Pitch Financials Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Pettinga Financial Advisors Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Wall Street Business Network Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Franklin Credit Management Corporation Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Crawford Financial Planning Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet SearchBug Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WorldNetDaily Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Marketplace Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Ulitzer Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Ulitzer Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Sys-Con Media Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational.. Media name/outlet ADVFN India Country India Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet TickerTech.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Bio-Medicine Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Barchart Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Pharmacy Choice Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Indianapolis Business Journal Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet U-T San Diego Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet PR Newswire UK Country United Kingdom Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Fox 19 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WSFA Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KFVE Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KCBD Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WAND TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WLOX Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet State Journal Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KOLD-TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet ABC6.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WAFF Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Channel 8 Eyewitness News Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WALB 10 Country Georgia Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WLBT Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KRHD TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WIS-TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KPLC TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KXXV-TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WFLX Fox 29 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Hawaii News Now Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Nebraska TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet 14 WFIE Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WMCTV.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WFMJ 21 - TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KXNet.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KiiiTV3.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KHQ Right Now Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WVNS Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet ABC News 4 Charleston Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KTRE Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WSFX-TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet FOX 14 TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KSLA Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet CW Richmond WUPV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KYTX CBS 19 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KTEN.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KFMB-TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KTVN Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet GTN News Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KFVS12 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet 35 WSEE Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WECT TV-6 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KSTC-TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Kait 8 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WBOY Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KLTV 7 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KCEN HD Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WDAM-TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet NBC12 Online Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Fox41.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet AZ-TV7 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet 12 News Now Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KUSI.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WLTZ 38 Country Georgia Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WBOC TV 16 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KSWO Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet 19 Action News Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KOTV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KNDO KNDU Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KAUZ Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WTOL-TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet KWES NewsWest 9 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Wave 3 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Kuam News 8 Country Guam Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet 3 WRCB-TV Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WTVM Country Georgia Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet MyFoxTallahassee.com Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WXTX Fox 54 Country Georgia Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WAFB Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WTOC TV Country Georgia Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WTRF Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet News 9 Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Live 5 WCSC Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet WMBF Country United States Date 11/16/15 Persons Fred Poordad Title AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Media name/outlet Informazione.it Country Italy Date 11/16/15 Persons Fred Poordad